![Anti-F. tularensis LVS 50S Ribosomal Protein L7/L12 (Rp1L) [109]](https://cancertools.org/wp-content/uploads/35afca9c-9589-4bfd-8cdd-39e72cb85f8e.png)
Cat. #154035
Anti-F. tularensis LVS 50S Ribosomal Protein L7/L12 (Rp1L) [109]
Cat. #: 154035
Unit size: 100 ug
Availability: 10-12 weeks
Target: 50S Rb protein L7/L12 (Rp1L)
Class: Monoclonal
Application: ELISA ; IF ; IP ; WB
Reactivity: Francisella tularensis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne Savitt
Institute: Stony Brook University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-F. tularensis LVS 50S Ribosomal Protein L7/L12 (Rp1L) [109]
- Research fields: Microbiology
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 13 kDa
- Reactivity: Francisella tularensis
- Host: Mouse
- Application: ELISA ; IF ; IP ; WB
- Description: The mouse IgG2a monoclonal antibody is reactive against both F. tularensis LVS and F. tularensis SchuS4 protein 50S Rb protein L7/L12 (Rp1L) (does not react with F. novicida). Francisella tularensis is a small pathogenic gram-negative bacterium that causes tularemia.
- Immunogen: Sublethal infection with F. tularensis LVS
- Isotype: IgG2a
Target Details
- Target: 50S Rb protein L7/L12 (Rp1L)
- Molecular weight: 13 kDa
- Target background: The mouse IgG2a monoclonal antibody is reactive against both F. tularensis LVS and F. tularensis SchuS4 protein 50S Rb protein L7/L12 (Rp1L) (does not react with F. novicida). Francisella tularensis is a small pathogenic gram-negative bacterium that causes tularemia.
Applications
- Application: ELISA ; IF ; IP ; WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Dry ice
References
- Savitt et al. 2009. Clin Vaccine Immunol. 16(3):414-22. PMID: 19176692.
- Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.
